Vigabatrin
Links shared publicly online about this topic
Pediatrics Medical News about vigabatrin
mdlinx.com — “MRI changes associated with vigabatrin treatment mimicking tumor progression” View full resource at mdlinx.com
Most Recently Shared on June 29, 2010 at 10:22 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
MRI changes associated with vigabatrin treatment mimicking tumor progression: Pediatric Blood & Cancer http://bit.ly/8YbqU1 #peds
Pediatrics Medical News about Spasms, Infantile Vigabatrin
mdlinx.com — “Vigabatrin for the Treatment of Infantile Spasms: Final Report of a Randomized Trial” View full resource at mdlinx.com
Most Recently Shared on April 20, 2010 at 10:56 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Vigabatrin for the Treatment of Infantile Spasms: Final Report of a Randomized Trial: Journal of Child Neurology http://bit.ly/9DaGBd #peds
Vigabatrin Treatment and Visual Field Loss - QualityPoint Technologies
qualitypointtech.net — “Vigabatrin is an efficacious new-generation antiepileptic drug, but it's rarely given to adults because of its retinal toxicity. When is its use warranted? Nature Reviews Neurology” View full resource at qualitypointtech.net
Most Recently Shared on April 11, 2011 at 11:35 am By:
Vigabatrin Treatment and Visual Field Loss: Vigabatrin is an efficacious new-generation antiepileptic drug, but it... http://bit.ly/h2FXao
Neurology Medical News about Anticonvulsants Vigabatrin Lacosamide Rufinamide
mdlinx.com — “New Antiepileptic Drugs: Lacosamide, Rufinamide, and Vigabatrin” View full resource at mdlinx.com
Most Recently Shared on June 2, 2010 at 11:07 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
New Antiepileptic Drugs: Lacosamide, Rufinamide, and Vigabatrin: Current Treatment Options in Ne... http://bit.ly/an0oPO #neurology #mdlinx
Catalyst's CPP-115 improves retinal safety profile than vigabatrin
news-medical.net — “Catalyst Pharmaceutical Partners, Inc. today announced positive results from a series of CPP-115 preclinical safety and efficacy evaluations. CPP-115 was found to have a significantly improved retinal safety profile compared to vigabatrin.” View full resource at news-medical.net
Most Recently Shared on November 1, 2010 at 4:08 pm By:
Epilepsy News: Catalyst’s CPP-115 improves retinal safety profile than vigabatrin: Catalyst Pharmaceutical Partner... http://bit.ly/cvHQa4
Catalyst Pharmaceutical Partners' vigabatrin data to be presented at 41st ASAM conference
news-medical.net — “Catalyst Pharmaceutical Partners, Inc. today announced that on Friday April 16th, Eugene C. Somoza, MD, PhD, University of Cincinnati College of Medicine and VA Medical Center, Cincinnati, OH will present a paper he authored along with Charles Gorodetzky, MD, PhD, Douglas Winship and Peggy Somoza, entitled: "A Multi-Site, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Vigabatrin (VGB) for Treating Cocaine Dependence"” View full resource at news-medical.net
Most Recently Shared on April 9, 2010 at 1:34 pm By:
Catalyst Pharmaceutical Partners' vigabatrin data to be presented at 41st ASAM conference: Catalyst Pharmaceutical... http://bit.ly/bwUIu8
EPO grants Brookhaven patent for use of vigabatrin in prevention of addiction to opioids
news-medical.net — “Catalyst Pharmaceutical Partners, Inc. today announced that the European Patent Office (EPO) granted to Brookhaven Science Associates/Brookhaven National Laboratory (Brookhaven) a European patent for the use of vigabatrin for the prevention of addiction to opioids (e.g., oxycodone, hydrocodone) used in pain management.” View full resource at news-medical.net
Most Recently Shared on July 9, 2010 at 1:33 pm By:
EPO grants Brookhaven patent for use of vigabatrin in prevention of addiction to opioids: Catalyst Pharmaceutical ... http://bit.ly/b7jSwH
First Post-Baseline Data from the Sabril(R) (vigabatrin) Registry Presented at the American Epilepsy Society Annual Meeting - MarketWatch
marketwatch.com — “First Post-Baseline Data from the Sabril(R) (vigabatrin) Registry Presented at the American Epilepsy Society Annual Meeting - MarketWatch” View full resource at marketwatch.com
Most Recently Shared on December 5, 2011 at 1:00 pm By:
Wils Eye's Robert Sergott, MD, presented post-baseline vision data on Sabril therapy at AES annual meeting, 12/4/11. http://t.co/I79onXAw
Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial -- Darke et al. 95 (5): 382 -- Archives of Disease in Childhood
adc.bmj.com — “Darke, Katrina; Edwards, Stuart W; Hancock, Eleanor; Johnson, Anthony L; Kennedy, Colin R; Lux, Andrew L; Newton, Richard W; O'Callaghan, Finbar J K; Verity, Christopher M; Osborne, John P” View full resource at adc.bmj.com
Most Recently Shared on May 10, 2010 at 11:57 pm By:
Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin ... http://bit.ly/d1OQcl
Weight Loss From Addiction Drug
webmd.com — “Vigabatrin, now being tested as a treatment for cocaine addiction, lessens obese rats' craving for food. They lose about 20% of their body weight.” View full resource at webmd.com
Most Recently Shared on August 20, 2008 at 4:30 pm By:
WebMD Health News Weight Loss From Addiction Drug: Vigabatrin, now being tested as a .. http://tinyurl.com/5mc6w9
Sabril Approved by FDA to Treat Spasms in Infants and Epileptic Seizures
fda.gov — “Sabril (vigabatrin) oral solution has been approved by the u.s. food and drug administration to treat infantile spasms in children ages 1 month to 2 years. sabril is the first drug in the united states approved to treat the disorder, characterized by a severe type of seizure that usually appears in the first year of life, typically between ages 4 months and 8 months. the disorder can be debilitating because of the frequency of difficult-to-control daily seizures.” View full resource at fda.gov
Most Recently Shared on August 21, 2009 at 6:04 pm By:
eyeonfda Pharma and Health Lawyer
Sabril Approved by FDA to Treat Spasms in Infants and Epileptic Seizures http://bit.ly/2Hwoh
Sabril Approved By FDA To Treat Spasms In Infants And Epileptic Seizures
medicalnewstoday.com — “Sabril (vigabatrin) Oral Solution has been approved by the U.S. Food and Drug Administration to treat infantile spasms in children ages 1 month to 2 years. Sabril is the first drug in the United S” View full resource at medicalnewstoday.com
Most Recently Shared on August 24, 2009 at 2:47 pm By:
MNT Neurology News Neurology and Health News
Sabril Approved By FDA To Treat Spasms In Infants And Epileptic Seizures: Sabril (vigabatrin) Oral Solution has .. http://bit.ly/3ySvRQ
Lundbeck Inc. Announces FDA Marketing Approval for Sabril for the Treatment of Two Difficult-to-Treat Epilepsies
drugs.com — “Sabril (vigabatrin) is used to treat infantile spasms and complex partial seizures. Includes Sabril side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on August 23, 2009 at 3:44 am By:
Lundbeck Inc. Announces FDA Marketing Approval for Sabril - http://bit.ly/JYKTQ
Only Some Epilepsy Drugs Increase Risk of Suicide | Psych Central News
psychcentral.com — “A new study has determined that only some epilepsy drugs increase the risk for suicide. Currently, the Food and Drug Administration (FDA) requires a warning of” View full resource at psychcentral.com
Most Recently Shared on July 27, 2010 at 11:33 am By:
News: Only Some Epilepsy Drugs Increase Risk of Suicide http://bit.ly/b3wBIi
Certain Epilepsy Drugs May Increase Risk Of Suicide
medicalnewstoday.com — “While the Food and Drug Administration (FDA) requires a warning of an increased risk of suicide for all epilepsy drugs, a new study shows that only certain drugs may increase the risk. The study i” View full resource at medicalnewstoday.com
Most Recently Shared on July 28, 2010 at 2:06 pm By:
Certain Epilepsy Drugs May Increase Risk Of Suicide http://mnt.to/3GFH #epilepsy
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
MedicalFeed
Medical news and updates about medical articles and discussion in Google knols and in many medical websites.
Advertisement
